Table 2: Comparison of demographic and clinical features in SLE patients with and without AP.

SLE with AP SLE without AP

Female (%)25 (92.59%)20 (86.96%)0.42
Age on SLE diagnosis (y) 0.26
GCs dose (mg) 0.18
SLEDAI score 0.03
SLICC/ACR damage index 0.11
Mortality10 (37.04%)00.001
Fever (%)21 (77.78%)9 (39.13%)0.006
Neuropsychiatric (%)7 (25.93%)1 (4.35%)0.042
Pulmonary (%)11 (40.74%)5 (21.74%)0.13
Articular (%)16 (59.26%)16 (69.57%)0.32
Mucocutaneous involvement (%)18 (66.67%)16 (69.57%)0.54
Renal (%)24 (88.89%)20 (86.96%)0.59
Hepatological (%)19 (82.61%)8 (34.78%)0.01
Hematological (%)27 (100.00%)14 (60.87%)0.001
Serositis (%)17 (62.96%)6 (26.09%)0.01
Number of organs involved 0.001
Positive anti-dsDNA (%)24 (88.89%)19 (82.61%)0.41
Positive anti-Sm (%)6/21 (28.57%)10 (43.48%)0.24
Positive anti-Ro (%)13/21 (61.90%)14 (60.87%)0.60
Positive anti-La (%)7/21 (33.33%)00.003
Positive ACL-IgG (%)4/21 (19.05%)1/22 (4.55%)0.168
Positive ACL-IgM (%)4/21 (19.05%)1/22 (4.55%)0.16
Positive anti- GPI (%)3/21 (14.29%)2/22 (9.09%)0.48
Low C3 (%)26/26 (100%)22 (95.65%)0.47
Low C4 (%)21/26 (80.77%)20 (86.96%)0.42
Elevated CRP (%)18/22 (81.82%)10/21 (47.62%)0.02